Total Payments
$449,712
2024 Payments
$109,917
Companies
55
Transactions
1,182
Medicare Patients
18,149
Medicare Billing
$1.6M
Payment Breakdown by Category
Other$219,249 (48.8%)
Research$126,349 (28.1%)
Consulting$54,374 (12.1%)
Travel$25,144 (5.6%)
Food & Beverage$24,143 (5.4%)
Education$446.43 (0.1%)
Gifts$6.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $212,838 | 83 | 47.3% |
| Unspecified | $126,349 | 46 | 28.1% |
| Consulting Fee | $54,374 | 21 | 12.1% |
| Travel and Lodging | $25,144 | 69 | 5.6% |
| Food and Beverage | $24,143 | 942 | 5.4% |
| Honoraria | $6,411 | 4 | 1.4% |
| Education | $446.43 | 15 | 0.1% |
| Gift | $6.46 | 2 | 0.0% |
Payments by Type
General
$323,363
1,136 transactions
Research
$126,349
46 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $106,266 | 177 | $0 (2024) |
| Eli Lilly and Company | $68,454 | 33 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $53,984 | 88 | $0 (2024) |
| Galderma Laboratories, L.P. | $49,799 | 104 | $0 (2024) |
| Krystal Biotech Inc | $37,388 | 49 | $0 (2024) |
| Bausch Health US, LLC | $26,829 | 6 | $0 (2019) |
| Dermavant Sciences, Inc. | $22,966 | 65 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $19,074 | 40 | $0 (2024) |
| Pierre Fabre Pharmaceuticals, Inc. | $11,550 | 18 | $0 (2024) |
| Amryt Pharma Holdings Ltd | $9,853 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $109,917 | 252 | Krystal Biotech Inc ($28,559) |
| 2023 | $51,008 | 207 | PFIZER INC. ($24,803) |
| 2022 | $50,635 | 156 | PFIZER INC. ($19,874) |
| 2021 | $22,428 | 109 | Regeneron Healthcare Solutions, Inc. ($11,544) |
| 2020 | $16,226 | 48 | Novartis Pharmaceuticals Corporation ($5,439) |
| 2019 | $58,461 | 124 | Regeneron Healthcare Solutions, Inc. ($19,198) |
| 2018 | $74,789 | 145 | Eli Lilly and Company ($28,574) |
| 2017 | $66,246 | 141 | Galderma Laboratories, L.P. ($29,637) |
All Payment Transactions
1,182 individual payment records from CMS Open Payments — Page 1 of 48
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $13.67 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | LITFULO (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: LITFULO CLINICAL PUBLICATION PROGRAM • Category: IMMUNOLOGY | ||||||
| 12/17/2024 | Chiesi USA, Inc. | FILSUVEZ (Drug) | Honoraria | Cash or cash equivalent | $300.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $29.10 | General |
| Category: Immunology | ||||||
| 12/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $35.76 | General |
| 12/16/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $12.81 | General |
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Immunology | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $10.55 | General |
| Category: Dermatology | ||||||
| 12/04/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Travel and Lodging | Cash or cash equivalent | $136.11 | General |
| Category: DERMATOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: ONCOLOGY | ||||||
| 11/30/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $500.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/22/2024 | Verrica Pharmaceuticals Inc. | YCANTH (Drug) | Travel and Lodging | Cash or cash equivalent | $21.44 | General |
| Category: DERMATOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,775.00 | General |
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Immunology | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $34.84 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Consulting Fee | Cash or cash equivalent | $8,140.00 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $493.96 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $282.56 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Travel and Lodging | In-kind items and services | $220.54 | General |
| Category: DERMATOLOGY | ||||||
| 11/16/2024 | Dermavant Sciences, Inc. | TAPINAROF (Drug) | Food and Beverage | In-kind items and services | $134.71 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, OPEN LABEL, SINGLE-ARM STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF EFINACONAZOLE 10 TOPICAL SOLUTION IN SUBJECTS WITH MILD TO SEVERE ONYCHOMYCOSIS OF THE TOENAILS | Bausch Health US, LLC | $24,246 | 3 |
| EFFICACY AND SAFETY OF ADAPALENE 0.35BENZOYL PEROXIDE 2.5 GEL PLUS DOXYCYCLINE IN SEVERE INFLAMMATORY ACNE NON-NODULOCYSTIC SUBJECTS | Galderma Laboratories, L.P. | $18,220 | 3 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $17,111 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $15,418 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $9,118 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $6,974 | 4 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,833 | 2 |
| A PHASE 3 DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | Eli Lilly and Company | $5,832 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH COSENTYX RESEARCH | Novartis Pharmaceuticals Corporation | $4,375 | 1 |
| LITFULO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $3,194 | 1 |
| A PHASE 3 MULTICENTER, DOUBLE-BLIND STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN ADULT PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $3,194 | 1 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,996 | 6 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $2,148 | 3 |
| MULTI-CENTER, OPEN-LABEL, SINGLE-ARM, STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF EFINACONAZOLE 10 TOPICAL SOLUTION IN PEDIATRIC SUBJECTS WITH MILD TO SEVERE ONYCHOMYCOSIS OF THE TOENAILS | Bausch Health US, LLC | $1,378 | 1 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris | Bausch Health US, LLC | $1,205 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $600.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $500.27 | 3 |
| PEDIATRIC STUDY IN CHILDREN WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Novartis Pharmaceuticals Corporation | $317.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $229.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $156.55 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 4,101 | 19,321 | $1.2M | $383,177 |
| 2022 | 37 | 3,789 | 16,224 | $1.1M | $357,124 |
| 2021 | 33 | 5,176 | 27,004 | $1.5M | $462,041 |
| 2020 | 33 | 5,083 | 25,767 | $1.4M | $439,743 |
Total Patients
18,149
Total Services
88,316
Medicare Billing
$1.6M
Procedure Codes
134
All Medicare Procedures & Services
134 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 919 | 1,318 | $263,150 | $75,240 | 28.6% |
| 77280 | Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | Office | 2023 | 13 | 164 | $59,600 | $34,220 | 57.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 421 | 480 | $119,560 | $30,144 | 25.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 339 | 381 | $76,100 | $29,227 | 38.4% |
| 96910 | Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | Office | 2023 | 16 | 320 | $48,000 | $29,051 | 60.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 574 | 753 | $112,800 | $27,653 | 24.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 398 | 398 | $79,350 | $27,186 | 34.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 201 | 285 | $57,050 | $25,023 | 43.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 107 | 127 | $56,650 | $16,041 | 28.3% |
| J7345 | Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 2023 | 22 | 11,200 | $22,400 | $14,522 | 64.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 466 | 2,909 | $72,545 | $14,200 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 86 | 86 | $21,500 | $8,614 | 40.1% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 21 | 22 | $17,600 | $7,150 | 40.6% |
| 77401 | Superficial and/or low voltage radiation treatment delivery | Office | 2023 | 13 | 192 | $28,730 | $6,057 | 21.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 112 | 153 | $38,070 | $5,924 | 15.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 23 | 24 | $10,800 | $5,217 | 48.3% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 17 | 45 | $13,500 | $4,892 | 36.2% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 24 | 26 | $8,320 | $3,144 | 37.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 82 | 86 | $17,200 | $2,982 | 17.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 18 | 19 | $9,880 | $2,073 | 21.0% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 12 | 14 | $5,600 | $2,062 | 36.8% |
| 69100 | Biopsy of ear | Office | 2023 | 38 | 40 | $8,000 | $1,957 | 24.5% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 19 | 19 | $8,740 | $1,818 | 20.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 19 | 19 | $5,225 | $1,690 | 32.4% |
| 11642 | Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 11 | 12 | $6,000 | $1,675 | 27.9% |
About Dr. John Browning, MD
Dr. John Browning, MD is a Pediatric Dermatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124181615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Browning, MD has received a total of $449,712 in payments from pharmaceutical and medical device companies, with $109,917 received in 2024. These payments were reported across 1,182 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($212,838).
As a Medicare-enrolled provider, Browning has provided services to 18,149 Medicare beneficiaries, totaling 88,316 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 134 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Dermatology
- Location San Antonio, TX
- Active Since 12/18/2006
- Last Updated 02/26/2025
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1124181615
Products in Payments
- CIBINQO (Drug) $53,065
- EUCRISA (Drug) $49,026
- EPIDUO FORTE (Drug) $39,794
- VYJUVEK (Drug) $37,388
- JUBLIA (Drug) $24,321
- TALTZ (Drug) $17,812
- TAPINAROF (Drug) $16,932
- COSENTYX (Biological) $12,150
- HEMANGEOL (Drug) $11,550
- VTAMA (Drug) $6,034
- QBREXZA (Drug) $5,160
- COSENTYX (Drug) $4,869
- DUPIXENT (Biological) $4,341
- FILSUVEZ (Drug) $3,880
- LITFULO (Drug) $3,200
- YCANTH (Drug) $3,051
- Cloderm Cream (Drug) $2,671
- ENSTILAR (Drug) $2,447
- Sernivo Spray 120ml (Drug) $1,673
- RINVOQ (Biological) $1,404
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.